

A Functional Rat Model of Upper Extremity Tourniquet-Induced Ischemia Reperfusion Injury

Omar A. Selim, MBBCh, MSc; Aida Sarcon, MD; Ichiro Tsukamoto, MD; Ramona Reisdorf, BSc; Chunfeng Zhao, MD; Steven L. Moran, MD


Purpose: Skeletal muscle ischemia reperfusion injury (IRI) remains a clinical challenge in orthopaedic and trauma practices. There is limited consensus on the optimal model or methodology to study IRI effects on extremity function *in vivo*. Most studies have used the mouse hindlimb, which does not reflect the anatomical or functional complexity of the upper extremity. The purpose of this study was twofold: (1) to establish and validate a reproducible model of tourniquet-induced extremity IRI, and (2) to investigate the impact of upper limb tourniquet use in upper extremity function.

Methods: A unilateral tourniquet-induced IRI (2.5 h ischemia time) was established in the forelimb of Sprague-Dawley rats using a commercially available exsanguinating device. Ischemia and reperfusion were confirmed both clinically and quantified using laser speckle contrast imaging. Functional evaluation was performed using gait kinematics and *in vivo* electrodiagnostic studies at different reperfusion timepoints. Compound muscle action potential (CMAP) was evoked by incremental and supramaximal stimulation of the brachial plexus using current intensity of 1-20 mA; frequency, 10Hz; filter settings, 1 Hz-10kHz. Serum biochemical markers of muscle injury were evaluated using automated chemistry analyzer. Histological staining and neuromuscular junction immunostaining were also performed.


Results: Tourniquet application resulted in significant reduction in forelimb perfusion ($P = 0.0013$) and its release re-established baseline flow ($P = 0.0006$). Significant differences were found between CMAP negative peak amplitude and area compared to baseline parameters up to 2 weeks post-IRI ($P < 0.0001$). No significant difference was seen between onset latency across all time points following reperfusion ($P > 0.1$). Serum Creatine Kinase was significantly higher following 3-hour reperfusion ($P = 0.011$). Serum lactate dehydrogenase was statistically significant both following 3-h ($P = 0.002$) and 24-h reperfusion ($P = 0.0161$). Neuromuscular junction immunohistochemistry revealed denervation at both 24 and 48 h following reperfusion. Histological analysis revealed polymorphonuclear infiltrates and sarcoplasm loss.

Conclusion: A forelimb rat IRI model presented here could provide functional insights and elucidate electrophysiologic alterations associated with upper extremity tourniquet use. Nerve conduction study and immunohistochemistry findings are consistent with conduction block and denervation, respectively. The CMAP size, represented by amplitudes and areas of the biphasic waveform, represents a sensitive and clinically applicable parameter for evaluating post-tourniquet induced-IRI denervation recovery. Gait analysis could be useful in later time points following IRI induction.


A Tourni-Cot® device for IRI induction




Laser Speckle Contrast Imaging for Forelimb IRI validation



B In vivo forelimb electrophysiology for IRI




Gait analysis following IRI



Loss of normal gait dynamics up to 48 h after reperfusion.

Gait restored after 5 days of injury consistent with CMAP recovery.

C Serum creatine kinase, Serum aspartate transaminase, Serum Lactate Dehydrogenase, Blood Urea Nitrogen, Serum Creatinine



D Normal rat skeletal muscle, Skeletal muscle 24 hours following IRI, Normal rat skeletal NMJ, NMJ at 48 h




Figure 1: Rat forelimb upper extremity IRI model: A) Tourni-Cot tourniquet device; validation of ischemia and reperfusion using laser speckle contrast imaging. B) Representative CMAP tracings (10 mV/div and 2 ms/div) and gait kinematics. Left upper tracing: normal CMAP morphology (stimulation artefact-1: onset latency; 1-3: negative peak; 2-4: peak-peak amplitude; 1-5: total duration). C) Serum chemistry panel. D) Representative histological images of skeletal muscles at different reperfusion timepoints (yellow arrowhead: RBCs extravasation, white arrow: hypercontracted injured myofiber, blue arrow: neutrophil infiltration). E) NMJ Immunostaining (α -bungarotoxin: stain postsynaptic receptors, 2H3 and SV2: anti neurofilament and pansynaptic vesicle marker).

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device they wish to use in clinical practice.